Condition: Coronary Artery Disease · Percutaneous Coronary Intervention · Acute Coronary Syndrome · Sponsor: Duk-Woo Park, MD
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known cardiac and vascular disease receiving chronic use of antithrombotic drugs (either antiplatelets, OAC, and its combinations) who are at high GI bleeding risk. The primary hypothesis is that P-CAB (experimental arm) would non-inferior to PPI (standard arm) with respect to the rate of the primary composite end point of GI events at 12 months after randomization.
This description comes directly from the study's public registry record.
Jeong-youn Bae, RN · 82230107259 · cvcrc10@amc.seoul.kr
Always discuss trial participation with your own doctor first.
| Hallym University Sacred Heart Hospital | Anyang, South Korea | Recruiting |
| Bucheon Sejong Hospital | Bucheon-si, South Korea | Recruiting |
| Kosin University Gospel Hospital | Busan, South Korea | Recruiting |
| Gyeongsang National University Changwon Hospital | Changwon, South Korea | Withdrawn |
| Sungkyunkwan University Samsung Changwon Hospital | Changwon, South Korea | Withdrawn |
| Dankook University Hospital | Cheonan, South Korea | Withdrawn |
| Chungbuk National University Hospital | Cheonju, South Korea | Recruiting |
| Gangwon National Univ. Hospital | Chuncheon, South Korea | Not Yet Recruiting |
| Hallym University Chuncheon Sacred Heart Hospital | Chuncheon, South Korea | Not Yet Recruiting |
| Keimyung University Dongsan Medical Center | Daegu, South Korea | Recruiting |
| Yeungnam University Medical Center | Daegu, South Korea | Withdrawn |
| Chungnam National University Hospital | Daejeon, South Korea | Recruiting |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04416581